BMO Capital Maintains Market Perform on CytomX Therapeutics, Lowers Price Target to $3.25
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout maintains a Market Perform rating on CytomX Therapeutics (CTMX) and lowers the price target from $3.3 to $3.25.
March 12, 2024 | 3:11 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BMO Capital maintains a Market Perform rating on CytomX Therapeutics and lowers the price target from $3.3 to $3.25.
The adjustment in price target by BMO Capital is minor, suggesting a neutral outlook on CTMX's stock price in the short term. The maintenance of a Market Perform rating indicates no significant change in the company's fundamentals or market position.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100